Feverfew in rheumatoid arthritis: a double blind, placebo controlled study

• Published in: Annals of the rheumatic diseases Vol. 48; no. 7; pp. 547 - 549
• Main Authors: Pattrick, M, Heptinstall, S, Doherty, M
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and European League Against Rheumatism 01-07-1989; BMJ; BMJ Publishing Group LTD
• Subjects: Adult; Aged; Arthritis, Rheumatoid - drug therapy; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Plant Extracts - therapeutic use; Plants, Medicinal; Prospective Studies; Random Allocation; Sesquiterpenes - therapeutic use; Tanacetum parthenium; Human; Antiinflammatory agent; Diseases of the osteoarticular system; Oral administration; Inflammatory joint disease; Compositae; Chemotherapy; Chronic; Treatment; Dicotyledones; Rheumatoid arthritis; Angiospermae; Plant origin; Spermatophyta
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/ard.48.7.547

Feverfew, reputed by folklore to be effective in arthritis, has in vitro properties that could be beneficial in the control of inflammatory disease. Forty one female patients with symptomatic rheumatoid arthritis received either dried chopped feverfew (70-86 mg) or placebo capsules once daily for six weeks. Allocation was random and not known by patient or observer. Variables assessed included stiffness, pain (visual analogue scale), grip strength, articular index, full blood count, erythrocyte sedimentation rate, urea, creatinine, C reactive protein, complement breakdown products (C3dg), rheumatoid factor titre, immunoglobulins (IgG, IgA, IgM), functional capacity, and patient and observer global opinions. One patient (placebo) withdrew after three days and was not included in the analysis. Treatment and placebo groups (20 patients each) were well matched at entry. No important differences between the clinical or laboratory variables of the groups were observed during the six week period. This study therefore shows no apparent benefit from oral feverfew in rheumatoid arthritis.